• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 12, 2024 at 11:52: AM
via The FDA on Thursday greenlit the label expansion of AstraZeneca’s subcutaneous IL-5 receptor blocker Fasnera (benralizumab), which can now be used as an add-on maintenance treatment for severe eosinophilic asthma in children six to 11 years of age.

article source
 




Top Bottom
Back
Quote